

Krishna J Rocha-Singh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9221811/publications.pdf>

Version: 2024-02-01

35
papers

3,115
citations

331259

21
h-index

360668

35
g-index

38
all docs

38
docs citations

38
times ranked

1975
citing authors

#	ARTICLE	IF	CITATIONS
1	Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease. <i>New England Journal of Medicine</i> , 2015, 373, 145-153.	13.9	558
2	Peripheral arterial calcification: Prevalence, mechanism, detection, and clinical implications. <i>Catheterization and Cardiovascular Interventions</i> , 2014, 83, E212-20.	0.7	391
3	Drug-Eluting Balloon Versus Standard Balloon Angioplasty for Infrapopliteal Arterial Revascularization in Critical Limb Ischemia. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1568-1576.	1.2	327
4	Performance goals and endpoint assessments for clinical trials of femoropopliteal bare nitinol stents in patients with symptomatic peripheral arterial disease. <i>Catheterization and Cardiovascular Interventions</i> , 2007, 69, 910-919.	0.7	214
5	Lower Extremity Revascularization Using Directional Atherectomy. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 923-933.	1.1	210
6	Directional Atherectomy Followed by a Paclitaxel-Coated Balloon to Inhibit Restenosis and Maintain Vessel Patency. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	1.4	180
7	Embolic Protection and Platelet Inhibition During Renal Artery Stenting. <i>Circulation</i> , 2008, 117, 2752-2760.	1.6	163
8	Evaluation of the Safety and Effectiveness of Renal Artery Stenting After Unsuccessful Balloon Angioplasty. <i>Journal of the American College of Cardiology</i> , 2005, 46, 776-783.	1.2	150
9	Mortality and Paclitaxel-Coated Devices. <i>Circulation</i> , 2020, 141, 1859-1869.	1.6	122
10	The United States Study for Evaluating Endovascular Treatments of Lesions in the Superficial Femoral Artery and Proximal Popliteal By using the Protégé Everflex Nitinol Stent System II (DURABILITY II). <i>Journal of Vascular Surgery</i> , 2013, 58, 73-83.e1.	0.6	115
11	Clinical predictors of improved long-term blood pressure control after successful stenting of hypertensive patients with obstructive renal artery atherosclerosis. <i>Catheterization and Cardiovascular Interventions</i> , 1999, 47, 167-172.	0.7	82
12	Long-term renal function preservation after renal artery stenting in patients with progressive ischemic nephropathy. <i>Catheterization and Cardiovascular Interventions</i> , 2002, 57, 135-141.	0.7	80
13	Renal artery stenting with noninvasive duplex ultrasound follow-up: 3-year results from the RENAISSANCE renal stent trial. <i>Catheterization and Cardiovascular Interventions</i> , 2008, 72, 853-862.	0.7	68
14	Excimer laser with adjunctive balloon angioplasty and heparin-coated self-expanding stent grafts for the treatment of femoropopliteal artery in-stent restenosis. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 80, 852-859.	0.7	64
15	Major adverse limb events and wound healing following infrapopliteal artery stent implantation in patients with critical limb ischemia: The XCELL trial. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 80, 1042-1051.	0.7	59
16	A single stent strategy in patients with lifestyle limiting claudication: 3-year results from the Durability II trial. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 86, 164-170.	0.7	47
17	An analysis of IN.PACT DEEP randomized trial on the limitations of the societal guidelines-recommended hemodynamic parameters to diagnose critical limb ischemia. <i>Journal of Vascular Surgery</i> , 2016, 63, 1311-1317.	0.6	43
18	Directional atherectomy before paclitaxel coated balloon angioplasty in complex femoropopliteal disease: The <sc>VIVA REALITY</sc> study. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, 549-558.	0.7	33

#	ARTICLE	IF	CITATIONS
19	Functional and clinical outcomes of nitinol stenting with and without abciximab for complex superficial femoral artery disease: A randomized trial. <i>Catheterization and Cardiovascular Interventions</i> , 2006, 67, 288-297.	0.7	28
20	Patient-level meta-analysis of 999 claudicants undergoing primary femoropopliteal nitinol stent implantation. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, 1250-1256.	0.7	20
21	Drug-coated balloons to improve femoropopliteal artery patency: Rationale and design of the LEVANT 2 trial. <i>American Heart Journal</i> , 2015, 169, 479-485.	1.2	16
22	Objective performance goals of safety and blood pressure efficacy for clinical trials of renal artery bare metal stents in hypertensive patients with atherosclerotic renal artery stenosis. <i>Catheterization and Cardiovascular Interventions</i> , 2011, 78, 779-789.	0.7	11
23	Glycoprotein IIb/IIIa receptor inhibition with eptifibatid in percutaneous intervention for symptomatic peripheral vascular disease: The circulate pilot trial. <i>Catheterization and Cardiovascular Interventions</i> , 2005, 66, 470-473.	0.7	6
24	Feasibility of FiberNet® embolic protection system in patients undergoing angioplasty for atherosclerotic renal artery stenosis. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 79, 430-436.	0.7	6
25	Combined glycoprotein IIb/IIIa receptor inhibition and low-dose fibrinolysis for peripheral arterial thrombosis. <i>Catheterization and Cardiovascular Interventions</i> , 2002, 55, 457-460.	0.7	5
26	Renal Sympathetic Denervation for Treatment-Resistant Hypertension in Moderation. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1887-1889.	1.2	5
27	Analysis of IN.PACT DEEP trial on the association between changes in perfusion from pre- to postrevascularization and clinical outcomes in critical limb ischemia. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 90, 986-993.	0.7	5
28	Angiographic classification of patterns of restenosis following femoropopliteal artery intervention: A proposed scoring system. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 90, 639-646.	0.7	5
29	One-year clinical outcomes and relative costs of primary infarct artery stenting versus angioplasty following systemic thrombolysis for acute myocardial infarction. <i>Catheterization and Cardiovascular Interventions</i> , 2000, 49, 135-141.	0.7	4
30	Aortorenal artery translesion pressure gradients in renovascular hypertension: In search of clinical significance. <i>Catheterization and Cardiovascular Interventions</i> , 2003, 59, 378-379.	0.7	4
31	One balloon, one stent: An effective cost-containment strategy for elective stent deployment. , 1997, 40, 17-20.		3
32	Percutaneous renal artery intervention for preservation of renal function: Strategies for identification of at-risk patients. <i>Catheterization and Cardiovascular Interventions</i> , 2006, 68, 507-512.	0.7	3
33	Retrospective Real-World Studies of Paclitaxel and Mortality. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2062-2064.	1.1	2
34	The Ranger Low-Dose Paclitaxel Drug-Coated Balloon. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 1134-1136.	1.1	1
35	Update on Lower Extremity Endovascular Interventions. <i>Journal of Interventional Cardiology</i> , 1998, 11, S66-S72.	0.5	0